GlassScriptPhysician profile
Charmaine Capistrano
NPI 1730774316
$2,670.62
in general payments reported to CMS, 2019-2025
22 companies · $358 in 2025
The $358 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $895 · 2022: $567 · 2023: $420 · 2024: $431 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,209.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $475.85 | 2021-2025 | Renasys Touch, Grafix Pl, Stravix |
| Kerecis Limited | $419.51 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Kci USA, INC. | $406.58 | 2021-2023 | V.A.C. Veraflo |
| Abbvie INC. | $315.66 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $283.73 | 2021-2023 | Breztri |
| Novo Nordisk INC | $131.70 | 2021 | |
| Gilead Sciences, INC. | $124.98 | 2023 | |
| Organogenesis INC. | $122.35 | 2022 | |
| Medtronic, INC. | $72.81 | 2025 | Mazor X System |
| Paratek Pharmaceuticals, INC. | $50.74 | 2022-2024 | Nuzyra |
| Bayer Healthcare Pharmaceuticals INC. | $39.90 | 2021 | |
| Mannkind Corporation | $30.16 | 2021 | |
| Solventum Corporation | $28.13 | 2024 | Activ.A.C. |
| Lilly USA, LLC | $24.20 | 2021 | |
| Integra Lifesciences Corporation | $23.43 | 2025 | Tcc-Ez |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $22.14 | 2021 | |
| Horizon Therapeutics Plc | $21.72 | 2022 | |
| Amarin Pharma, INC. | $19.20 | 2021 | |
| Glaxosmithkline, LLC. | $14.96 | 2023 | Arexvy, Shingrix |
| Biohaven Pharmaceuticals, INC. | $14.90 | 2021 | |
| Medela LLC | $14.53 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charmaine Capistrano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.